Hamad A, Yusubalieva GM et al (2023) Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies. Viruses. https://doi.org/10.3390/v15020547
Article PubMed PubMed Central Google Scholar
Louis DN, Perry A et al (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
Article CAS PubMed PubMed Central Google Scholar
Tan AC, Ashley DM et al (2020) Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70:299–312. https://doi.org/10.3322/caac.21613
Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM (2020) Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep 10(1):11622. https://doi.org/10.1038/s41598-020-68011-4
Article CAS PubMed PubMed Central Google Scholar
Davis ME (2016) Glioblastoma: overview of disease and treatment. Clin J Oncol Nursing 20:S2-8. https://doi.org/10.1188/16.CJON.S1.2-8
Schaff LR, Mellinghoff IK (2023) Glioblastoma and other primary brain malignancies in adults: a review. JAMA 329:574–587. https://doi.org/10.1001/jama.2023.0023
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003. https://doi.org/10.1056/NEJMoa043331
Article CAS PubMed Google Scholar
Stragliotto G, Pantalone MR, Rahbar A, Bartek J, Söderberg-Naucler C (2020) Valganciclovir as add-on to standard therapy in glioblastoma patients. Clin Cancer Res 26(15):4031–4039. https://doi.org/10.1158/1078-0432.Ccr-20-0369
Article CAS PubMed Google Scholar
Scherm A, Ippen FM, Hau P et al (2023) Targeted therapies in patients with newly diagnosed glioblastoma—a systematic meta-analysis of randomized clinical trials. Int J Cancer 152(11):2373–2382. https://doi.org/10.1002/ijc.34433
Article CAS PubMed Google Scholar
Ji N, Weng D et al (2016) Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget 7:4369–4378. https://doi.org/10.18632/oncotarget.6737
Wang JL, Scheitler KM, Wenger NM, Elder JB (2021) Viral therapies for glioblastoma and high-grade gliomas in adults: a systematic review. Neurosurg Focus 50(2):E2. https://doi.org/10.3171/2020.11.Focus20854
Carpenter AB, Carpenter AM, Aiken R, Hanft S (2021) Oncolytic virus in gliomas: a review of human clinical investigations. Ann Oncol 32(8):968–982. https://doi.org/10.1016/j.annonc.2021.03.197
Article CAS PubMed Google Scholar
Smith GL, Banegas MP, Acquati C et al (2022) Navigating financial toxicity in patients with cancer: a multidisciplinary management approach. CA Cancer J Clin 72(5):437–453. https://doi.org/10.3322/caac.21730
Rodrigues R, Duarte D et al (2022) Drug repurposing in cancer therapy: influence of patient’s genetic background in breast cancer treatment. Int J Mol Sci 23:4280. https://doi.org/10.3390/ijms23084280
Article CAS PubMed PubMed Central Google Scholar
Curran M, Noble S (2001) Valganciclovir. Drugs 61(8):1145–1150. https://doi.org/10.2165/00003495-200161080-00013
Article CAS PubMed Google Scholar
Yang T, Liu D et al (2022) Cytomegalovirus and glioblastoma: a review of the biological associations and therapeutic strategies. J Clin Med 11:5221. https://doi.org/10.3390/jcm11175221
Article CAS PubMed PubMed Central Google Scholar
Rainov NG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Therap 11:2389–2401. https://doi.org/10.1089/104303400750038499
Immonen A, Vapalahti M et al (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Therap 10:967–972. https://doi.org/10.1016/j.ymthe.2004.08.002
Stragliotto G, Rahbar A et al (2013) Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer 133:1204–1213. https://doi.org/10.1002/ijc.28111
Article CAS PubMed Google Scholar
Westphal M, Ylä-Herttuala S et al (2013) Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 14:823–833. https://doi.org/10.1016/S1470-2045(13)70274-2
Article CAS PubMed Google Scholar
Sherin DR, Manojkumar TK (2021) Exploring the selectivity of guanine scaffold in anticancer drug development by computational repurposing approach. Sci Rep 11(1):16251. https://doi.org/10.1038/s41598-021-95507-4
Article CAS PubMed PubMed Central Google Scholar
Karjoo Z, Chen X, Hatefi A (2016) Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev 99(Pt A):113–128. https://doi.org/10.1016/j.addr.2015.05.009
Article CAS PubMed Google Scholar
Boeckh M, Ljungman P (2009) How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113:5711–5719. https://doi.org/10.1182/blood-2008-10-143560
Article CAS PubMed PubMed Central Google Scholar
Stragliotto G, Pantalone MR et al (2020) Valganciclovir as add-on to standard therapy in glioblastoma patients. Clin Cancer Res 26:4031–4039. https://doi.org/10.1158/1078-0432.CCR-20-0369
Article CAS PubMed Google Scholar
Rahbar A, Orrego A et al (2013) Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol 57:36–42. https://doi.org/10.1016/j.jcv.2012.12.018
Rahbar A, Stragliotto G et al (2012) Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival; —a case-control study. Herpesviridae 3:3. https://doi.org/10.1186/2042-4280-3-3
Article PubMed PubMed Central Google Scholar
Culver KW, Ram Z, Wallbridge S et al (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256(5063):1550–1552. https://doi.org/10.1126/science.1317968
Article CAS PubMed Google Scholar
Ram Z, Culver KW, Oshiro EM et al (1997) Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3(12):1354–1361. https://doi.org/10.1038/nm1297-1354
Article CAS PubMed Google Scholar
Amano S, Gu C, Koizumi S, Tokuyama T, Namba H (2011) Tumoricidal bystander effect in the suicide gene therapy using mesenchymal stem cells does not injure normal brain tissues. Cancer Lett 306(1):99–105. https://doi.org/10.1016/j.canlet.2011.02.037
Article CAS PubMed Google Scholar
Oishi T, Ito M, Koizumi S et al (2022) Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases. Mol Ther Methods Clin Dev 26:253–265. https://doi.org/10.1016/j.omtm.2022.07.001
Article CAS PubMed PubMed Central Google Scholar
Li S, Gu C, Gao Y et al (2012) Bystander effect in glioma suicide gene therapy using bone marrow stromal cells. Stem Cell Res 9(3):270–276. https://doi.org/10.1016/j.scr.2012.08.002
Article CAS PubMed Google Scholar
Page MJ, Shamseer L, Tricco AC (2018) Registration of systematic reviews in PROSPERO: 30,000 records and counting. Syst Rev 7(1):32. https://doi.org/10.1186/s13643-018-0699-4
Article PubMed PubMed Central Google Scholar
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71
Article PubMed PubMed Central Google Scholar
Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898
Comments (0)